文献速递泌尿生殖与妇科肿瘤放疗

放疗联合短期雄激素阻断及阿比特龙治疗中高危局限前列腺癌

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-11-28

这项前瞻性2期单臂试验纳入37例低体积中危或高危局限前列腺癌患者,给予6个月ADT联合阿比特龙+泼尼松及放疗。12个月PSA不可测率为55%,36个月PFS为96%,81%患者睾酮恢复,中位恢复时间9.2个月。3级毒性32%,主要为高血压,无≥4级毒性。

要点

  • 6个月ADT联合阿比特龙+泼尼松与放疗联用,3级毒性32%,无≥4级毒性。
  • 12个月PSA不可测率55%,36个月PFS 96%。
  • 81%患者睾酮恢复,中位恢复时间9.2个月,性激素功能24个月改善。

核心结论

  • 放疗联合6个月ADT及阿比特龙+泼尼松在低体积中高危局限前列腺癌中毒性可接受,睾酮恢复率高且疾病控制优异。

研究设计与样本

  • 前瞻性2期单臂试验,纳入37例低体积预后不良中危或高危局限前列腺癌男性,45%为高危。
  • 所有患者为T1-2期且PSA<20 ng/mL,接受6个月ADT同步阿比特龙+泼尼松每日一次及前列腺和精囊放疗。

主要发现

  • 中位随访37个月(95%CI 35.7-39.1),32%发生与阿比特龙+泼尼松相关的3级毒性,主要为高血压,无≥4级毒性。
  • 12个月PSA不可测率为55%(95%CI 36%-72%)。
  • 中位随访46个月时,2/37例出现PSA进展,36个月PFS为96%(95%CI 76%-99%)。
  • 81%患者睾酮恢复,中位恢复时间9.2个月;性激素功能在6个月下降,24个月改善。

临床怎么用

  • 对于低体积中危或高危局限前列腺癌,可考虑放疗联合6个月ADT及阿比特龙+泼尼松方案,需监测高血压等毒性。
  • 该方案可能实现较短疗程雄激素抑制并促进睾酮恢复,但需前瞻性对照研究进一步验证。

局限性

  • 单臂2期试验,样本量37例,随访时间有限,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of more potent but shorter-term androgen inhibition in men with intermediate- or high-risk localized PC would synergize with definitive RT to provide short-term testosterone recovery and improve disease control. METHODS AND MATERIALS: This prospective phase 2 single-arm trial enrolled men with low-volume unfavorable intermediate or high-risk localized PC. Treatment included 6 months of ADT concurrent with abiraterone acetate plus prednisone (AAP) once daily and RT to prostate and seminal vesicles. The primary endpoint was the proportion of men with an undetectable prostate-specific antigen (PSA) at 12-months; secondary objectives included biochemical progression-free survival (PFS), testosterone recovery, toxicity, and sexual and hormonal quality of life. RESULTS: We enrolled 37 men between January 2014 and August 2016, 45% of whom were high risk. All patients had T1-2 disease and PSA < 20 ng/mL. Median follow-up is 37 months (95% confidence interval [CI], 35.7-39.1). Treatment noted 32% grade 3 toxicities related to AAP, predominantly hypertension, with no toxicities ≥G4. The rate of undetectable PSA at 12 months was 55% (95% CI, 36%-72%). With 46 months of median follow-up, 2 of 37 patients developed PSA progression (36-month PFS = 96%; 95% CI, 76%-99%), and 81% of patients recovered testosterone with a median time to recovery of 9.2 months. Hormonal or sexual function declined at 6 months with subsequent improvement by 24 months. CONCLUSIONS: The combination of RT and 6 months of ADT and AAP demonstrated acceptable toxicity and a high rate of testosterone recovery with restoration of quality of life and excellent disease control in men with low-volume, intermediate- or high-risk localized prostate cancer. Prospective comparative studies are justified.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Koontz BF, Hoffman KE, Halabi S, et al. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 33259932. doi:10.1016/j.ijrobp.2020.11.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。